CMMI Director Discusses Aduhelm Coverage

October 19, 2021

Center for Medicare and Medicaid Innovation (CMMI) Director Elizabeth Fowler recently discussed Biogen’s Aduhelm drug. She noted that Congress first needs to make a decision regarding drug pricing before Medicaid policy regarding the drug can be set.

“Medicaid’s pharmacy director says the Biogen Alzheimer’s drug is ‘currently a covered outpatient drug.’ As the payer of last resort, Medicaid could find itself significantly impacted by a Medicare national coverage decision.” Read more here.

(Source: Ramsey Baghdadi, Pink Sheet, 10/4/21)

Share This Story!